hrp0095p1-286 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Sulphonylurea for Improving Neurological Features in Neonatal Diabetes: a systematic review and meta-analyses

de Gouveia Buff Passone Caroline , Giani Elisa , Vaivre-Douret Laurence , Karayawasam Dulandjalee , Berdugo Marianne , Garcin Laure , Beltrand Jacques , Marques Bernardo Wanderley , Polak Michel

Background: In monogenic diabetes due to KCNJ11 and ABCC8 mutations that impair KATP- channel function, sulphonylureas improve long-term glycaemic control. Although KATP channels are extensively expressed in the brain, the effect of sulphonylureas on neurological function has varied widely. We evaluated published evidence about potential effects of sulphonylureas on neurological features, especially epilepsy, cognition, motor function and muscular tone, visuo-...

hrp0095p1-34 | Diabetes and Insulin | ESPE2022

Early treatment of neonatal diabetes with oral glibenclamide suspension (Amglidia®) in an extremely preterm infant: evidence for efficacy, safety and easiness.

Galderisi Alfonso , Kermorvant-Duchemin Elsa , Daruich Alejandra , Alice Bonnard Adeline , Lapillonne Alexandre , Aubelle Marie-Stéphanie , Perrella Bruna , Cave Héléne , Berdugo Marianne , Jarreau Pierre-Henri , Polak Michel , Beltrand Jacques

Background: Early treatment of neonatal diabetes with sulfonylureas has shown to improve neurodevelopment, beyond the demonstrated efficacy on glycemic control. Several barriers still prevent its use as an early treatment in preterm babies including the limited availability of a suitable galenic form of glibenclamide. Recently, an oral suspension of glibenclamide (Amglidia®) has been approved for use in EU.Methods: W...